Ahmedabad: The Ahmedabad Municipal Corporation has written to the Gujarat Food and Drug Control Administration (FDCA) after receiving complaints about "lapses" in clinical trials on humans being conducted by some city-based laboratories, said an official on Wednesday. According to the corporation's medical officer of health, Dr Bhavin Solanki, the complaints mostly concern the lack of appropriate care and treatment during and after the clinical trials. Also Read: Unequal Trials in New Drug Approvals: CDSCO Seeks Feedback for Policy Reform "AMC's Health Department has received complaints about lapses in clinical research on humans being conducted by some laboratories. It was alleged that these labs were not providing proper care and treatment during and after clinical trials," said Solanki. It was also alleged that the participants of the trials were videographed by these firms without their consent, he said. "Since the issue is related to the clinical trials, we have shared the details with the FDCA for further action," he added. Also Read: Anticoagulant Monotherapy alone, best for Stroke Prevention in AF with Atherosclerosis: JAMA
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!